Pasar al contenido principal

DECIFRANDO NUEVOS LOCI GENETICOS Y SUS CONSECUENCIAS EN LA PATOLOGIA DE LAS ENFERMEDADES INFLAMATORIAS A TRAVES DE UNA NUEVA ESTRATEGIA DE FENOTIPADO MOLECULAR

PID2020-113776GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD, M.P.

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut epithelial barrier dysfunction in lupus triggers a differential humoral response against gut commensals

  • Botía-Sánchez, María
  • Galicia, Georgina
  • Albaladejo-Marico, Lorena
  • Toro-Domínguez, Daniel
  • Morell, María
  • Marcos-Fernández, Raquel
  • Margolles Barros, Abelardo
  • Alarcón-Riquelme, Marta E.
Introduction: Systemic lupus erythematosus is an autoimmune disease with multisystemic involvement including intestinal inflammation. Lupus-associated intestinal inflammation may alter the mucosal barrier where millions of commensals have a dynamic and selective interaction with the host immune system. Here, we investigated the consequences of the intestinal inflammation in a TLR7-mediated lupus model. Methods: IgA humoral and cellular response in the gut was measured. The barrier function of the gut epithelial layer was characterised. Also, microbiota composition in the fecal matter was analysed as well as the systemic humoral response to differential commensals. Results: The lupus-associated intestinal inflammation modifies the IgA B cell response in the gut-associated lymphoid tissue in association with dysbiosis. Intestinal inflammation alters the tight junction protein distribution in the epithelial barrier, which correlated with increased permeability of the intestinal barrier and changes in the microbiota composition. This permeability resulted in a differential humoral response against intestinal commensals. Discussion: Lupus development can cause alterations in microbiota composition, allowing specific species to colonize only the lupus gut. Eventually, these alterations and the changes in gut permeability induced by intestinal inflammation could lead to bacterial translocation., Support for this work was provided by the Marie Sklodowska Curie postdoctoral fellowship to GG and MA-R with Grant number GAP 838548, the Consejería de Salud y Familias, Junta de Andalucía grant PE-0297-2019 (MA-R), the Ministerio de Economía y Competitividad grant SAF2016-78631-P (MA-R), the Ministerio de Ciencia e Innovación grant PID2020-113776GB-100 (MA-R) and the Swedish Research Council, grant No 2022-01000 (MA-R)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A summary on the genetics of Systemic Lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren’s syndrome

  • Ortiz-Fernández, Lourdes
  • Martín, Javier
  • Alarcón-Riquelme, M. E.
Systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome are four major autoimmune rheumatic diseases characterized by the presence of autoantibodies, caused by a dysregulation of the immune system that leads to a wide variety of clinical manifestations. These conditions present complex etiologies strongly influenced by multiple environmental and genetic factors. The human leukocyte antigen (HLA) region was the first locus identified to be associated and still represents the strongest susceptibility factor for each of these conditions, particularly the HLA class II genes, including DQA1, DQB1, and DRB1, but class I genes have also been associated. Over the last two decades, the genetic component of these disorders has been extensively investigated and hundreds of non-HLA risk genetic variants have been uncovered. Furthermore, it is widely accepted that autoimmune rheumatic diseases share molecular disease pathways, such as the interferon (IFN) type I pathways, which are reflected in a common genetic background. Some examples of well-known pleiotropic loci for autoimmune rheumatic diseases are the HLA region, DNASEL13, TNIP1, and IRF5, among others. The identification of the causal molecular mechanisms behind the genetic associations is still a challenge. However, recent advances have been achieved through mouse models and functional studies of the loci. Here, we provide an updated overview of the genetic architecture underlying these four autoimmune rheumatic diseases, with a special focus on the HLA region., This work was supported by the Spanish Ministry of Science and Innovation RTI2018-101332-B-100 to JM and PID2020-113776 Gb-I00 to MEAR), Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER) from Instituto de Salud Carlos III (RD16/0012/0013 to JM), the Consejería de Salud y Familias (PE-0297–2019 to MEAR), and the Consejería de Transformación económica, industria, conocimiento y universidades (PY20-00473 to MEAR). LOF was funded by the Spanish Ministry of Science and Innovation through the Juan de la Cierva Incorporacion program (ref. IJC2019-040746-I)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants

  • Castellini-Pérez, Olivia
  • Povedano, Elena
  • Barturen, Guillermo
  • Martínez-Bueno, Manuel
  • Kerick, Martin
  • Marañón, Concepción
  • Martín, Javier
  • Ballestar, Estéban
  • Orietta Borghi, Maria
  • PRECISESADS Clinical Consortium
  • PRECISESADS Flow Cytometry Consortium
  • Carnero-Montoro, Elena
  • Alarcón-Riquelme, M. E.
PRECISEADS Clinical Consortium and PRECISEADS Flow Cytometry Study Group: et al., The heterogeneity of systemic lupus erythematosus (SLE) can be explained by epigenetic alterations that disrupt transcriptional programs mediating environmental and genetic risk. This study evaluated the epigenetic contribution to SLE heterogeneity considering molecular and serological subtypes, genetics and transcriptional status, followed by drug target discovery. We performed a stratified epigenome-wide association studies of whole blood DNA methylation from 213 SLE patients and 221 controls. Methylation quantitative trait loci analyses, cytokine and transcription factor activity - epigenetic associations and methylation-expression correlations were conducted. New drug targets were searched for based on differentially methylated genes. In a stratified approach, a total of 974 differential methylation CpG sites with dependency on molecular subtypes and autoantibody profiles were found. Mediation analyses suggested that SLE-associated SNPs in the HLA region exert their risk through DNA methylation changes. Novel genetic variants regulating DNAm in disease or in specific molecular contexts were identified. The epigenetic landscapes showed strong association with transcription factor activity and cytokine levels, conditioned by the molecular context. Epigenetic signals were enriched in known and novel drug targets for SLE. This study reveals possible genetic drivers and consequences of epigenetic variability on SLE heterogeneity and disentangles the DNAm mediation role on SLE genetic risk and novel disease-specific meQTLs. Finally, novel targets for drug development were discovered., Open access funding provided by Karolinska Institute., E.C.M and O.C.P have been funded by Grants for the financing of Research, Development, and Innovation (R + D + I) in Biomedicine and Health Sciences in Andalusia for the year 2021, project co-financed by 80% by funds of the FEDER Operational Program of Andalusia 2014-2020 (File Number: PECOVID-0072-2020). Funding for this work has been provided by the Plan Estatal, Ministerio de Ciencia e Innovación a MEAR No. PID2020-113776GB-I00, as well as to the Lupus Research Alliance/BMS Award to M.E.A.R. and the Diversity Supplement to O.C.P. Funding for the preparation of this manuscript has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115565, resources composed of the financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and the EFPIA companies’ in kind contribution and from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. The contributions of the consortia to this study are gratefully acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bank1 deficiency reshapes the gut microbiota of lupus mice towards an anti-inflammatory composition

  • Galicia, Georgina
  • Botía-Sánchez, María
  • Toro-Domínguez, Daniel
  • López García, Ana
  • Valera, Juan Rafael
  • Gómez Hernández, Gonzalo
  • Marcos-Fernández, Raquel
  • Carmona, Noelia
  • Luque, Gracia
  • Morell, María
  • Varela, Nieves
  • Pérez-Cozar, Francisco
  • Margolles Barros, Abelardo
  • Aguilera, Margarita
  • Alarcón-Riquelme, Marta E.
The author(s) declare that financial support was received for the research and/or publication of this article. The following funding was awarded to MEAR supported the work presented: MSCA- European grant (ROBE-838548) to support Galicia G, The Andalusian Consejería de Salud y Familias grant PE-0297–2019 including also support for the doctoral studies of MB-S, the Swedish Research Council grant 2022-01000, and the Spanish Ministerio de Ciencia e Innovación (MCII) grant PID2020-113776GB-I00.The B-cell scaffold protein with ankyrin repeats (BANK1) regulates Toll-like receptor-7 (TLR7) signaling in B cells and its absence ameliorates lupus. Here, we investigated the involvement of Bank1 in the gut mucosal B cell response to commensals in a murine model of lupus. In health and disease, Bank1 deficiency resulted in changes in the intestinal IgA production levels that showed differential bacterial binding associated with a re-organization on the composition and structure of the gut microbiota. Furthermore, the amelioration of lupus gut pathology in mice lacking Bank1 was linked to the increase of Parabacteroides distasonis that when vertically transmitted or orally administered, as emerging probiotic, reduced disease severity and repaired signs of distorted intestinal permeability. The increase of P. distasonis directly correlated with anti-inflammatory processes. In vitro stimulation either with P. distasonis or via TLR9 allowed for the differentiation of IL-10 producing B cells which, in vivo, differentially accumulated in the Peyer´s patches of Bank1-deficient lupus mice. Finally, the blood microbiome of lupus patients was found to be devoid of P. distasonis, whereas healthy controls exhibited the bacterium, thereby supporting the protective role of P. distasonis in the disease., The following funding was awarded to MEAR supported the work presented: MSCA- European grant (ROBE-838548) to support Galicia G, The Andalusian Consejería de Salud y Familias grant PE-0297–2019 including also support for the doctoral studies of MB-S, the Swedish Research Council grant 2022-01000, and the Spanish Ministerio de Ciencia e Innovación (MCII) grant PID2020-113776GB-I00., Peer reviewed